# Clinical Study on the Efficacy and Safety of RC48-ADC in the Treatment of Metastatic Castration Resistant Prostate Cancer (mCRPC)

> **NCT05955209** · PHASE2 · UNKNOWN · sponsor: **Peking University Cancer Hospital & Institute** · enrollment: 40 (estimated)

## Conditions studied

- Metastatic Castration-resistant Prostate Cancer

## Interventions

- **DRUG:** Disitamab Vedotin（RC48-ADC）

## Key facts

- **NCT ID:** NCT05955209
- **Lead sponsor:** Peking University Cancer Hospital & Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-08-01
- **Primary completion:** 2024-08-01
- **Final completion:** 2025-08-01
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2023-07-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05955209

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05955209, "Clinical Study on the Efficacy and Safety of RC48-ADC in the Treatment of Metastatic Castration Resistant Prostate Cancer (mCRPC)". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT05955209. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*